by Clinical Consulting Team This post was written by our guest author, Raushanah Najeeullah, ND. Breast cancer affects approximately one in eight women, making it one of the most common cancers worldwide. While genetic factors can influence breast cancer risk, lifestyle choices and early detection play an important role in prevention. Nutrient and hormone influences, and possibly estrogen metabolism, might be contributors to breast cancer development. Select use of testing and addressing results, could influence optimal breast health and may be associated with reducing breast cancer risk. The DUTCH Test (Dried Urine Test for Comprehensive Hormones) provides potential valuable insights ...

Author: Raushanah Najeeullah, ND A new urine test, MyProstateScore 2.0 (MPS2), offers better accuracy for detecting high-grade prostate cancer compared to current methods. In a recent study involving over 1,500 men, MPS2 reduced unnecessary biopsies by up to 51% while still identifying significant cancers with high sensitivity. This test improves on the PSA test by specifically targeting 17 genes linked to high grade aggressive prostate cancer, making it a promising non-invasive tool for reducing the risks and discomfort associated with prostate cancer screening. Source: Tosoian JJ, Zhang Y, Xiao L, et al. Development and Validation of an 18-Gene Urine Test ...

July 12, 2024 Leanna Standish IV CURCUMIN AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma.  Curcumin is the molecule present in turmeric root that has anticancer activity.  Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells.  We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth.  Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY.  Last year we presented ...